Ahjon81 Wednesday, 12/16/20 10:02:51 PM Re: None Post # of 129758 $EMOR financial report 12. Subsequent Events. On 1/02/2020 - Emerald gained exclusive worldwide development rights from Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS), to ESS, MANF and PhenoGuard FDA regulated therapeutics with Amarantus to receive Emerald preferred stock valued at a minimum of $66.6 million.” 33M shares of $EMOR will be issued to $AMBS